In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
about
Models of Respiratory Infections: Virus-Induced Asthma Exacerbations and BeyondPharmacodynamics of antimicrobials against Mycoplasma mycoides mycoides small colony, the causative agent of contagious bovine pleuropneumoniaDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingTime-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitroIn vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TBPredicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates.New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.PK/PD models in antibacterial development.A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of MoleculesDrug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization.The Role of Antibiotics in Modulating Virulence in Staphylococcus aureus.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.Pharmacokinetic and Pharmacodynamic Evaluation of Marbofloxacin in Pig against Korean Local Isolates of Actinobacillus pleuropneumoniae.Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.In vitro bactericidal activity of enrofloxacin against gyrA mutant and qnr-containing Escherichia coli isolates from animals.In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin after intravenous and intramuscular administration in beagle dogs.Translational Modeling of Antibacterial Agents
P2860
Q26786359-7A5D3C1B-B525-4264-ABAD-995B9B8A70F4Q28482671-AA78369D-FB1F-4E9B-A1B5-4797E757A18FQ28550711-99ECC19D-24C0-476D-98B1-D491EDD55FCAQ33802897-4E58C6E1-81EE-45A3-9A8D-51ED53DF7A9EQ34591451-3D4069BD-A348-43E7-919C-2A6B373F10C0Q34737629-E8518433-177B-4F84-8208-609A6F16F452Q35169065-F418A7B6-23C2-402C-B020-F61316E80969Q35616211-16FFAF3B-82A4-4D3B-AAB2-8F35638993F2Q36730017-56AB9EE7-894A-4BB8-A9CD-3C2B08AE274DQ36969966-120EAD41-1D85-493E-A0AA-CB1EB6E2084EQ37325658-81D8D046-2CB8-4ACD-B12F-E266EDD2CE3AQ37630801-6871C0AD-69C1-4B3E-BCA6-6C0D1B5C0D75Q37643787-16BC7ED9-2086-486F-9DD4-6100D0012682Q37949391-4981CBE2-088A-4223-84D9-BFF5AA5FE408Q38626980-9950F40C-86BE-41BC-9887-6D85D615E9AFQ38671478-D2E4ACF2-E3A1-47BB-A7FA-9D63A5B4BC27Q38837353-3927BE8D-3476-43A3-8CE1-45A9E8393FA1Q40087805-CAB379A8-79DB-45D5-A62B-527FBED44D5BQ40220513-BB4954C3-C8BE-4649-8C40-76AA3F0F34B2Q42227869-6DD17E8B-C772-4818-90C4-214B3014DFB6Q45564582-F660DD9C-7EA1-4DDD-B545-1B82C1F4FFDFQ51018579-694770BA-07B3-4FB8-946D-B2604527EFEFQ53247094-6305BED8-C11F-418C-ADC0-2D2B03A702B4Q57240408-476361EC-ED46-4D8D-8351-4234FDACEDF1
P2860
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
@en
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
@nl
type
label
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
@en
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
@nl
prefLabel
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
@en
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
@nl
P2093
P2860
P356
P1476
In vitro pharmacodynamic models to determine the effect of antibacterial drugs.
@en
P2093
Charlotte Kloft
Christian Scheerans
Hartmut Derendorf
Julia Gloede
P2860
P304
P356
10.1093/JAC/DKP434
P407
P577
2009-12-21T00:00:00Z